Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing; continued attack rate reduction over time In first-of-its-kind prospective analysis, patients switching from prior prophylactic treatment to donidalorsen experienced further reductions in mean monthly HAE attack rates from baseline Donidalorsen demonstrated a favorable safety and tolerability profile across all coh ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What ar ...

In a shortened week of trading following the Memorial Day weekend, investors may want to take notice of several medical stocks that were added to the Zacks Rank #1 (Strong Buy) list today. Standing out in terms of valuation with earnings estimates on the rise as well, here are three of these highly ranked medical stocks to consider. Haemonetics (HAE) Haemonetics is starting to stand out as a provider of blood management solutions to clients encompassing blood and plasma collectors, hospitals, and health car ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 28: MINISO Group Holding Limited (MNSO) : Thisinvestment holding company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 12.5% over the last 60 days. MINISO's shares gained 22.8% over the last three months compared with the S&P 500’s advance of 1.1%. The company possesses a Momentum Score of A. Lightspeed Commerce Inc. (LSPD) : This cloud servic ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock. In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks ...

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with po ...

Haemonetics (HAE) closed the last trading session at $88.64, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $112.20 indicates a 26.6% upside potential. The mean estimate comprises five short-term price targets with a standard deviation of $12.15. While the lowest estimate of $94 indicates a 6.1% increase from the current price level, the most optimistic analyst expect ...

Haemonetics (HAE) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Indiv ...

BOSTON, May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $525,000,000 aggregate principal amo ...

Haemonetics (HAE) is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company’s hospital portfolio is evolving and helping create new opportunities for growth and diversification. Strong financial stability also buoys optimism. Meanwhile, headwinds from economic uncertainties and adverse foreign exchange effects are concerns for Haemonetics’ operations. In the past year, this Zacks Rank #2 (Buy) stock has rallied 11.7% against the 1.3% fall of the indus ...